Oncology
TTX335Dx and TTX335o
Ovarian cancer begins in the ovaries, which produce and store eggs and churn out hormones that regulate a woman’s menstrual cycle as well as pregnancy. Worldwide, ovarian cancer is the leading cause of death for any cancer associated with the female reproductive system. It is the 8th most common cancer in women worldwide with more than 300,000 cases diagnosed each year.
Women with a family history of ovarian cancer are at greater risk as are those with genetic mutations that increase their likelihood of developing the disease. Endometriosis, obesity, and being of taller-than-average height also increase risk.
Ovarian cancer is notoriously difficult to detect early because women may not experience symptoms until more advanced stages. At that point, symptoms may include swelling or pressure in the abdomen, frequent need to urinate, feeling full quickly when eating, and GI problems such as bloating or constipation. Because these symptoms also can point to other conditions, the possibility of ovarian cancer may be overlooked.
As with so many diseases, ovarian cancer responds best to treatment when caught early.
More than 90 percent of women diagnosed at an early
stage of ovarian cancer survive longer than five years.
But only 20 percent of cases are discovered early.
Most cases of ovarian cancer are found at later stages not only because early-stage ovarian cancer is often asymptomatic but also because highly effective screening tests don’t exist.
It is difficult for physicians to feel early-stage ovarian tumors, and Pap or HPV tests don’t typically detect ovarian cancer. Transvaginal ultrasounds can identify ovarian tumors, but they can’t determine if they are cancer. A blood test that measures levels of a protein, CA-125 is useful to gauge whether treatment is working in women with ovarian cancer, but it has not proved very effective as a screening test.
1. Late and Difficult Detection.
Ovarian cancer develops quietly. Early symptoms are vague and easily mistaken for benign conditions. There are currently no reliable screening tools capable of detecting the disease at its earliest, most treatable stage. As a result, nearly 70% of women are diagnosed when the cancer has already spread, dramatically reducing survival outcomes.
300,000+
The number of new cases of ovarian cancer in 2020.
2. High Recurrence and Resistance.
While many patients initially respond to platinum-based chemotherapy, most experience relapse within two years. Each recurrence brings diminishing returns as the cancer becomes increasingly resistant to treatment. Over time, this transforms ovarian cancer into a chronic, treatment-resistant condition with limited options.
3. Biological Complexity, Uniform Treatment.
Ovarian cancer is not a single disease—it comprises multiple subtypes, each driven by distinct molecular mechanisms. Yet, most patients receive similar chemotherapy regimens. This “one-size-fits-all” approach fails to address the biological diversity that drives poor outcomes and limits therapeutic innovation.
Our mission is to change this. Temple Therapeutics is advancing biology-driven therapies designed to overcome resistance, target the root causes of disease progression, and improve outcomes for women worldwide.
We believe the future of ovarian cancer care lies in precision, not probability—and we’re building it now.
Ovarian cancer remains one of the most aggressive and least understood diseases in women’s health. Despite decades of research, survival rates have seen little improvement. At Temple Therapeutics, we are addressing the fundamental reasons why progress has been so slow. Using validated biobanks, we have uncovered novel targets, early detection biomarkers and key receptors, holding promise for precision and targeted therapeutics and diagnostics.
1. Late and Difficult Detection.
Ovarian cancer develops quietly. Early symptoms are vague and easily mistaken for benign conditions. There are currently no reliable screening tools capable of detecting the disease at its earliest, most treatable stage. As a result, nearly 70% of women are diagnosed when the cancer has already spread, dramatically reducing survival outcomes.
2. High Recurrence and Resistance.
While many patients initially respond to platinum-based chemotherapy, most experience relapse within two years. Each recurrence brings diminishing returns as the cancer becomes increasingly resistant to treatment. Over time, this transforms ovarian cancer into a chronic, treatment-resistant condition with limited options.
3. Biological Complexity, Uniform Treatment.
Ovarian cancer is not a single disease—it comprises multiple subtypes, each driven by distinct molecular mechanisms. Yet, most patients receive similar chemotherapy regimens. This “one-size-fits-all” approach fails to address the biological diversity that drives poor outcomes and limits therapeutic innovation.
Our mission is to change this. Temple Therapeutics is advancing biology-driven therapies designed to overcome resistance, target the root causes of disease progression, and improve outcomes for women worldwide.
We believe the future of ovarian cancer care lies in precision, not probability—and we’re building it now.